The role of CD4+ T cell responses in antitumor immunity

Curr Opin Immunol. 1998 Oct;10(5):588-94. doi: 10.1016/s0952-7915(98)80228-8.


While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, recent evidence indicates that CD4+ T cells are an equally critical component of the antitumor immune response. Successful immunity to cancer will therefore require activation of tumor-specific CD4+ T cells. Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors. These will provide the basis for new generations of antigen-specific tumor vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / analysis
  • CD4-Positive T-Lymphocytes / immunology*
  • Histocompatibility Antigens Class II / physiology
  • Humans
  • Immune Tolerance
  • Neoplasms / immunology*


  • Antigens, Neoplasm
  • Histocompatibility Antigens Class II